Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity - Wikidata - awgldk - TriplyDB

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

http://www.wikidata.org/entity/Q34701388

about

Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models Immunotherapeutic approaches for Alzheimer's disease The release and trans-synaptic transmission of Tau via exosomes Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency The intersection of amyloid beta and tau at synapses in Alzheimer's disease Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Novel immunological approaches for the treatment of Alzheimer's disease.Antibody-derived in vivo imaging of tau pathology.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Tau passive immunization inhibits not only tau but also Aβ pathology Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.Tau immunotherapy and imaging.Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.Harnessing the immune system for treatment and detection of tau pathology.Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.Invited review: Drug development for tauopathies.Tau Immunotherapy.Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations.Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody.Anti-tau antibody reduces insoluble tau and decreases brain atrophy Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach Tauopathies: Mechanisms and Therapeutic Strategies."Tau immunotherapy: Hopes and hindrances".Vaccination strategies in tauopathies and synucleinopathies.Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.

P2860

Q27308146-9EF7F705-4CD3-4551-B862-B2BBC138727F Q28081278-40365843-95C8-4CE5-B893-0D9F50253D94 Q28468594-F211AF1E-02C5-4BC2-926D-E350FAEEECE3 Q30805841-1186C786-E7BA-4909-B477-32CF6E55C40B Q33559937-FBB64D81-3DA2-46A2-B42C-53A5BAEB880E Q33640390-F7D20501-0EA1-4390-9C78-D1E7BE35545C Q34054680-1C96D640-4E62-4689-8185-8DCCE63E14C0 Q34205027-795CADB1-BD29-44FD-A9A1-8E36B99B784B Q34562675-08538C4B-C9A4-4076-813A-2DE48D08FDFB Q34664345-247FCB43-56F4-4F06-A26B-7298C8427FB9 Q34973787-30AD6DEB-9CD2-4A12-B37B-D0FEFEBBB894 Q35204878-F9DF2038-1909-470B-B90C-84C3E3EC059F Q35542169-CF6DA29C-7365-4E25-AC16-43A7AB78EA74 Q35624263-5F402516-C6C3-4C64-87E5-6C155115DFD5 Q35745135-37915372-AB80-4B24-B8A7-594C7F445B4D Q36395623-BFEFFA4D-6342-4E0B-A62E-4A7010EE8EB3 Q36484413-248538E2-DBBB-46B0-91A6-CC25676AF0C4 Q36558485-57F3C9A9-975A-4D57-8869-2CF161283433 Q37311364-B8952E14-C339-4F05-B178-F522342DAB98 Q37368709-D07BA532-86A5-4A37-93AE-257D95DC94A4 Q37566888-C217756F-52FF-4049-812E-FD6C0E9C6A6C Q37579019-B55239F2-6B1B-47BF-8F58-398D3DC133B7 Q37610545-BE3AA3CB-1EF5-460C-85A3-85CF1677D844 Q38136880-85B7BD2F-6EAE-46F7-AA9B-5E1C9715F9CF Q38175453-B339E0B9-ED81-47D6-9B53-4AFD4AC7EFDB Q38194049-DB168B51-3D05-46EE-9306-816CA009F3C9 Q38204620-99399AF2-A246-4082-9F8D-8131D4563EE0 Q38263698-64139BE4-DDA3-40C6-B8D5-BB4E47D35EF3 Q38628672-E6BCBDC8-7A30-4000-99C4-9FEDE1F07891 Q38634954-EEF4F6E9-287A-4BD3-A093-0952313BCE4B Q38912261-EBEBF7A9-BAEF-46FE-8C9C-E04E2E183D5B Q40239437-06F16554-0EF4-4198-8C81-82BCCF8C32FF Q40854182-54747B1A-BD55-4345-B0AB-A809B5322B6F Q41150186-1610B47F-E2E1-457E-9ABF-0D79B0AE444B Q41196178-8D59BCBD-4494-4A91-8758-937EBF728782 Q41629521-E2D4E82C-77AB-4445-889F-FD19A153000C Q47253592-8A73FFB4-17B1-4446-A4C5-4E4DF693C629 Q47629452-7B2636D8-FC94-4583-891A-0BEDA1DB9460 Q47860105-612E5036-BDBC-4FCC-83AF-2D8086BCCCB2 Q48532697-6BBDA100-2678-4901-8D92-4A1A70C946B6

P2860

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

http://www.wikidata.org/entity/Q34701388

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@ast

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@en

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@nl

type

label

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@ast

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@en

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@nl

prefLabel

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@ast

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@en

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@nl

P1433

Q34701388-5A57C327-9585-4935-BC96-DD0B7435A64B

P1476

Q34701388-E3191560-7E3D-4B8D-BF2D-AEE0A3E2474B

P2093

Q34701388-BDDC6D9B-440C-4474-9D9A-4EE1CC678D54

Q34701388-D3EAB990-1983-4C3B-9E11-6E1228CE41E1

Q34701388-ECF447F2-5568-48E2-9BC0-B50EB99EEC69

Q34701388-EF5119EE-772E-4934-88B1-7A0D5E0BD3C5

P2860

Q34701388-04526C87-1889-47ED-BA0F-D4BEE7B41576

Q34701388-1092D994-C44E-4646-83A0-7C54CA76D936

Q34701388-1167BA20-D1A8-4DDE-94CD-666C1A1CF716

Q34701388-1D30664C-5DFF-4BB7-9427-CA64F312A43C

Q34701388-1DCCB60F-EE72-4004-90AB-BF6DEF86C976

Q34701388-2180FBA5-4172-4F25-920E-014E92876D42

Q34701388-21A6C931-DED4-4650-BB0D-A8C8A60D6D37

Q34701388-2325C6FD-964D-4AA0-BF99-64289E69D7C4

Q34701388-275AD7CA-CF56-46FD-9CA3-0195956B9AB7

Q34701388-377B3C6D-2753-43B4-8007-8D27F4DDD797

P304

Q34701388-68C51B09-5B16-496D-8990-7A7E0AD40B3F

P31

Q34701388-EAFB3EFA-B19F-428C-BE6E-3E0924A3519F

P356

Q34701388-B8F06368-6ABE-4E88-99B3-D346A6240073

P407

Q34701388-49A380D0-E67F-4BC9-870D-99FB2540B56D

P433

Q34701388-DD168F1C-A013-496E-AB87-552AE6C90935

P478

Q34701388-5823308B-9CFA-4D35-8738-EFF12D49FE54

P577

Q34701388-1474CC72-EA6D-4363-BE7A-25F64ABAF9C9

P5875

Q34701388-F9D10773-6A6A-4F61-A811-A636FB972119

P698

Q34701388-F57A3EAF-4F9C-4189-9FE8-F9A7D468CE48

P921

Q34701388-3F44C3ED-AC1D-4756-B7C6-785BD75CA6C3

Q34701388-FC957810-3227-47B3-9E16-A6E86C732B23

P932

Q34701388-A1F53E93-67D5-4AC2-892D-C6AE18F5486C

P356

JOURNAL.PONE.0062402

P1433

P1476

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

@en

P2093

Christopher M Acker

http://www.w3.org/2001/XMLSchema#string

Cristina d'Abramo

http://www.w3.org/2001/XMLSchema#string

Heidy T Jimenez

http://www.w3.org/2001/XMLSchema#string

Peter Davies

http://www.w3.org/2001/XMLSchema#string

P2860

Is tau ready for admission to the prion club?

Transmission and spreading of tauopathy in transgenic mouse brain

Trans-synaptic spread of tau pathology in vivo

Propagation of tau pathology in a model of early Alzheimer's disease

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.

Hyperphosphorylation and cleavage at D421 enhance tau secretion

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

P304

e62402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0062402

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236604461

http://www.w3.org/2001/XMLSchema#string

P698

23638068

http://www.w3.org/2001/XMLSchema#string

P921

P932

3639259

http://www.w3.org/2001/XMLSchema#string